Market LIVE
Published markets; coverage varies by country
Product profile · United States

Omvoh

 ·  Patent Litigation & Settlement History ↓

Ingredientmirikizumab-mrkz
Application typeBLA
Application761279
Product001
Dosage formInjection
RouteIntravenous
Strength300MG/15ML (20MG/ML)
Approval date2023-10-26
Marketing statusPrescription
Status event—
ApplicantELI LILLY AND CO
Product source

Current GenericRadar decision

Year2035
SelectionDEEP_REVIEW
ReviewFINAL_CHECKING
Anchor typeREGULATORY_EXCLUSIVITY
Anchor date2035-10-26
Patent anchor2034-03-04
Exclusivity anchor2035-10-26
Protection date—
First Final ANDA—
Status event—

{"sequence":273,"product_key":"US:BLA:761279:001","judgment_status":"PROVISIONAL_EVIDENCE_SCREEN","review_basis":"LATER_RIGHT_SIGNAL","reason_codes":["LATER_PATENT_REFERENCE_DATE: US12152072"],"unknown_patent_terms":[],"pending_publications":[],"regulatory_anchor":"2035-10-26","later_regulatory_events":[],"batch":"BLA-05-06","review_version":"1.1","selection_status":"DEEP_REVIEW","verified":false,"anchor_status":"OPERATIONAL_UNVERIFIED","rights_anchor_date":"2035-10-26","patent_anchor_numbers":["US9023358"],"patent_term_verified":false,"canonical_judgment_confirmed":false,"first_biosimilar_approval_date":null,"first_final_generic_date":null,"has_existing_generic":null,"has_existing_biosimilar":null,"report":"BLA_05_06_50_JUDGMENT_20261021.html","report_sha256":"d3f5cba95e750a9f93f53184cc6d1c82c363bb5bb718ddbc60ccfe5c14efed29","regulatory_update_pending":true,"local_patent_review_pending":true,"FDA_followup":[{"issue":"FDA_RPE_DETERMINATION_AND_END_DATE_NOT_LOCATED","status":"UPDATE_PENDING","reason":"FDA PB target fields remain blank; no additional exact-target final determination located in the retrieved public FDA letters/review/administrative documents. Orange Book has no target BLA rows. Operational baseline retained with verified=false."}],"tail_patents":["US12152072"]}

Patent estate

PatentEffective dateOfficial listingTRUE_DSDS gradeClaim classification / basisPTEPEDFamily
US90233582034-03-04— —YNTRUE_DS
{"classification":"TRUE_DS","claim_count":7,"claim_number_coverage_complete":true,"reference_date_only":true,"official_current_term_verified":false,"commercial_product_mapping":"SUPPORTED_BY_PRIMARY_SEQUENCE_OR_STRUCTURE","batch":"BLA-05-06"}
———
US96887532034-03-04— ———QUALITY_PRODUCT_BY_PROCESS_REVIEW
{"classification":"QUALITY_PRODUCT_BY_PROCESS_REVIEW","claim_count":6,"claim_number_coverage_complete":true,"reference_date_only":true,"official_current_term_verified":false,"commercial_product_mapping":"NOT_ESTABLISHED","batch":"BLA-05-06"}
———
US121520722039-12-26— —NNU_PARTIAL_INDICATION_NON_DS_EQ
{"classification":"U_PARTIAL_INDICATION_NON_DS_EQ","claim_count":7,"claim_number_coverage_complete":true,"reference_date_only":true,"official_current_term_verified":false,"commercial_product_mapping":"NOT_ESTABLISHED","batch":"BLA-05-06"}
———

Regulatory exclusivity

CodeStart dateEnd dateScopeEntire productAll indicationsFull coverage dateCombinationSource
RPE_BASELINE2023-10-262035-10-26Full-product 12-year operational assumption; not FDA determinationYY——Source

2026-10-10 · PENDING_EXCLUSIVITY_CONFIRMATION · Historical coverage: NOT_COMPLETE

Generic approval evidence

Application / productEventFinal dateTentative dateApplicantAuthorized genericExact mappingSource
No generic approval facts are linked to this product.

Market Entry Information

API filings, authorized generics and linked regulatory milestones.

API Master Files & Certifications 0 records

Ingredient-level registrations from linked public manufacturer portfolios. A filing does not establish supply to this finished product. DMFs are not FDA approvals.

APIHolder / manufacturerHolder countryFiling typeNumberStatusFiled dateAvailable for referenceSourceLast verified
No master-file or certification records are linked through public manufacturer portfolios.

Authorized Generics 0 records

Authorized generics are shown separately from independent ANDA approvals.

Application / productApplicantEvent / status First marketed Product mappingSourceLast verified
No authorized-generic records are linked to this product.

Tentative ANDA Approvals 0 records

Tentative approval is not final approval. Historical tentative approvals remain visible after a linked final approval.

Application / productApplicantEvent / status Tentative date Follow-up final approvalProduct mappingSourceLast verified
No tentative-approval records are linked to this product.

Paragraph IV Challenges 0 records

Paragraph IV challenges below are sourced from legal records separately from FDA approvals. An ANDA filing, lawsuit or settlement does not establish final approval or commercial launch.

Application / productApplicantEvent / status Certification event date Product mappingSourceLast verified
No structured Paragraph IV certification events are linked in the available approval evidence.

Final ANDA Approvals 0 records

Approval dates do not establish commercial launch. Product mapping is shown for each linked record.

Application / productApplicantEvent / status Final approval date Product mappingSourceLast verified
No final-approval records are linked to this product.
Decision evidence (4)
TypeDateRoleBasisSource
PATENT2034-03-04ANCHOR_REFERENCEProduct scope reviewed; reference date only; current official term verification pendingSource
PATENT2034-03-04OTHER_RIGHT_REFERENCEProduct scope reviewed; reference date only; current official term verification pendingSource
PATENT2039-12-26OTHER_RIGHT_REFERENCEProduct scope reviewed; reference date only; current official term verification pendingSource
REGULATORY_EXCLUSIVITY2035-10-26ANCHOR_CALCULATIONUser-adopted operational baseline; inherited dates do not restart RPE; not FDA determinationSource
Independent legal-event information

Litigation & Settlement History

Settlement launch rights generally apply only to the named parties and product scope. These records do not change GenericRadar patent/exclusivity anchors or current decisions.

No litigation or settlement record currently linked to this product.